Note: Descriptions are shown in the official language in which they were submitted.
CA 03100248 2020-11-13
WO 2019/219693 PCT/EP2019/062360
1
CAPSULES WITH OPACIFIER
TECHNICAL FIELD
The present disclosure relates to formulations for the production of opaque
capsules or capsule
shells and opaque capsules made therefrom. Said capsules shield the ingredient
inside from light,
while retaining good mechanical properties. The invention also relates to
methods for making such
capsules and the use thereof for delivery of the ingredients.
BACKGROUND OF THE INVENTION
Certain medicaments or other active ingredients such as nutraceutical etc. are
sensitive to
degradation by light and need to be stored in a light-shielded manner. Within
capsules, the opacity
of the capsule hence regulates the light-shielding. Typically in the prior
art, titanium-dioxide (TiO2)
is used for creating opacity in the capsule shells.
Driven by the continuous search for new products, replacements of the well-
known opacifier were
sought.
There are many opacifiers, but due to their limited opacifying capacity, not
all of them will give the
capsules with good light blocking properties while maintaining the mechanical
strength required for
producing, processing and filling with active ingredient.
CaCO3 is defined as one of many potential opacifiers, light blocking agents,
light-shielding materials
or pigments in a number of patents or patent applications such as:
EP1580229A1, W02011143347,
W02015174868A1, EP1502588A1, U53784684, EP1757275A1, JP2003300872A,
U5200244970A1,
and U520100021535A1. However, none of these documents has documented
experimental success
with CaCO3 in term of obtaining both an opacifying effect and retaining
mechanical strength of
capsules, when incorporating the CaCO3 in the capsule formulation itself
rather than applying it in
some sort of coating on a capsule shell support. EP1574220A1 discloses the use
of calcium lactate
as an opacifier in HPMC-based capsules. Said calcium lactate however has a
rather low refractive
index and hence does not result in sufficient opacity. No information is given
on the mechanical
strength of such capsules.
Accordingly, it is an object of the present invention to provide capsules with
light-shielding
capacity, without the need of using TiO2, and still remaining good mechanical
properties.
CA 03100248 2020-11-13
WO 2019/219693 PCT/EP2019/062360
2
SUMMARY
The present invention relates to capsule shell formulation design focusing on
the selection of
opacifiers that reduce the light transmittance of capsules while retaining the
mechanical stability
needed for producing, storing, processing, filling etc. of said capsules.
The inventors have established that calcium carbonate (CaCO3), when present in
a specific
concentration range provided the best balance between good opacity and good
mechanical
properties, i.e. on the opacifying level and on the mechanical strength level
for capsules.
This was unexpected, since numerous publications have been reporting on the
potential use of
calcium carbonate as opacifier, however without showing actual results on both
opacity and
mechanical strength, when the opacifier is mixed within the capsule forming
formulation.
Having conducted extensive research on the matter, the inventors now put
forward the following
aspects of the invention:
Aspect 1. A capsule forming composition comprising:
- a film forming agent selected from the group consisting of: gelatin,
polysaccharides, modified
starches, cellulose derivatives or synthetic polymers or a combination
thereof; and
- an opacifying agent in the form of calcium carbonate, preferably
precipitated calcium carbonate,
in an amount of between 3 and 10 wt% based on dry weight of the capsule
forming formulation.
Aspect 2. The capsule forming composition according to aspect 1, wherein said
opacifying agent is
present in an amount of between 4 and 8 wt%, more preferably of between 5 and
7 wt%, such as
from 4.5 to 6.5 wt% based on dry weight of the capsule forming formulation.
Aspect 3. The capsule forming composition according to aspect 1 or 2, wherein
said calcium
carbonate has a substantially round or prismatic particle shape. In a
particular embodiment, the
calcium carbonate encompasses small round or prismatic uniform particles.
Aspect 4. The capsule forming composition according to any one of aspects 1 to
3, wherein said
CaCO3 has a median particle size of between 0.2 and 2.0 pm or a. D4,3 particle
size of about 10
pm or less.
The average particle size can be expressed as a "D50" (Dv50) median particle
size of between 0.2
to 2 pm, such as between 0.5 and 1.5 pm, more preferably of between 0.3 to 1.2
pm, more
preferably of between 0.4 to 1.1 pm, such as about 1 pm.
Alternatively, the particles can have a "D4,3" particle size of about 10 pm or
less, more preferably
of about 8 pm or less, such as about 6 pm or less, or about 4 pm or less, more
particularly of
CA 03100248 2020-11-13
WO 2019/219693 PCT/EP2019/062360
3
between 1 and 10 pm, or between 1 and 8 pm, preferably of between 2 and 6 pm,
more
preferably of about 4 pm, e.g. between 3.5 and 4.5 pm.
In one embodiment, the particle size distribution, defined as particle size
span, which is as low as
possible. Preferably, said span is lower than 15, such as lower than 10,
preferably below 8, more
preferably below 6.
Aspect 5. The capsule forming composition according to any one of aspects 1 to
4, having a
calcium carbonate concentration of about 10%, typically will have an opacity
coefficient of 20% or
higher. The capsule forming composition according to any one of aspects 1 to
4, having a calcium
carbonate concentration of about 5%, typically will have an opacity
coefficient of 15% or higher..
Alternatively, capsule forming composition according to any one of aspects 1
to 4 has a light
transmittance at 650 nm of 35% or lower when the capsule comprises 10% calcium
carbonate or a
light transmittance at 650 nm of 55% or lower when the capsule comprises 5%
calcium carbonate.
Aspect 6. The capsule forming composition according to any one of aspects 1 to
5, wherein said
calcium carbonate is in the form of precipitated calcium carbonate.
Aspect 7. The capsule forming composition according to any one of aspects 1 to
6, wherein said
film-forming agent is a cellulose based polymer such as methylcellulose,
hydroxymethylcellulose,
hyd roxypropylcel lu lose, methyl hyd roxyethylcel lu lose,
hyd roxypropyl methylcel lu lose,
hydroxypropylmethylcellulose phthalate,
hydroxypropylmethylcellulose acetate succi nate,
carboxymethylethylcellulose or a combination thereof, preferably
hydroxypropylmethylcellulose.
Aspect 8. The capsule forming composition according to any one of aspects 1 to
6, wherein said
film-forming agent is a synthetic polymer such as polyvinyl alcohol,
polyethylene glycol/oxide,
polyvinyl acetate, polyacrylamide, polyvinylacetal diethylamino acetate,
aminoalkylmethacrylate
copolymer E, polyvinylpyrolidone, or a combination thereof.
Aspect 9. The capsule forming composition according to any one of aspects 1 to
6, wherein said
film-forming agent is polypeptide- (protein-) based polymer such as gelatin,
collagen, zein, casein,
soy protein, or mung bean protein, whey protein, pea protein.
Aspect 10. The capsule forming composition according to any one of aspects 1
to 6, wherein said
film-forming agent is a polysaccharide, preferably pullulan, starch,
cellulose, or dextran.
Aspect 11. The capsule forming composition according to any one of aspects 1
to 6, wherein said
film-forming agent is an acrylate and/or (meth)acrylate based polymer such as
ethyl acrylate-
methyl methacrylate copolymer, polyacrylic acid, or polymethyl methacrylate.
Aspect 12. The capsule forming composition according to any one of aspects 1
to 11, further
comprising one or more additives such as: gelling agents, gelling aids,
viscosity modifiers, de-
CA 03100248 2020-11-13
WO 2019/219693 PCT/EP2019/062360
4
foaming aids, plasticizers, lubricants, colorants, solvents, solvent aids,
surfactants, dispersants,
solubilizers, stabilizers, correctives, sweeteners, adsorbents, adherent's,
antioxidants, antiseptics,
preservatives, desiccants, flavors, perfumes, anti-oxidants, pH adjusters,
binders, disintegrating
agents, release-controlling agents.
Aspect 13. A capsule formed from the capsule forming composition according to
any one of
aspects 1 to 12.
Preferably, said capsule comprises:
- a film forming agent selected from the group consisting of: gelatin,
polysaccharides, modified
starches, cellulose derivatives, or synthetic polymers; and
- an opacifying agent in the form of calcium carbonate in an amount of between
3 and 10 wt%
based on dry weight of the capsule forming composition, preferably in an
amount of between 4
and 8 wt%, more preferably of between 5 and 7 wt%, such as from 4.5 to 6.5 wt%
based on dry
weight of the capsule forming composition.
In a preferred embodiment, when said capsule comprises HPMC as film-forming
agent, the final
capsule will comprise from 4 to 6 wt.% water based on the total capsule
weight. In a further
preferred embodiment, when said capsule comprises gelatin as film-forming
agent the final capsule
will comprise from 12 to 15 wt.% of water based on the total capsule weight.
These concentrations
are based on ambient temperature and humidity (25 C (+/- 2 C) and RH of 30-
50%).
Aspect 14. The capsule according to aspect 13, which is a hard shell capsule,
preferably a gelatin,
pullulan or HPMC based hard shell capsule.
Aspect 15. A method of producing a capsule with reduced light transmittance
(also called opaque
capsules), comprising providing the film-forming composition according to any
one of clams 1 to
12, and forming capsules using a dip coating process.
Aspect 16. A method of preparing a film-forming composition according to any
one of aspects 1 to
12, comprising the steps of:
a) preparing an aqueous dispersion of calcium carbonate opacifier, through
mixing;
b) preparing a film-forming formulation comprising one or more film-forming
agent selected from
the group of: gelatin, polysaccharides, modified starches, cellulose
derivatives or synthetic
polymers or a combination thereof;
c) adding the aqueous dispersion of step a) to the solution of step b); and
d) mixing the resulting dispersion of step c), thereby obtaining the film
forming composition,
comprising between 3 and 10 wt%, preferably of between 4 and 8 wt%, more
preferably of
CA 03100248 2020-11-13
WO 2019/219693 PCT/EP2019/062360
between 5 and 7 wt%, such as from 4.5 to 6.5 wt% CaCO3 based on final dry
weight of the film-
forming composition. In one embodiment, said film-forming composition
comprises 15-25wt%
HPMC such as 20.5 wt% HPMC; or 25-35 wt%, such as about 31 wt% gelatin based
on total dry
weight of final capsule forming formulation.
5 Aspect 17. The method according to aspect 16, wherein step c) is
performed in two steps: c1)
adding a part of the film-forming formulation of step b) to the dispersion of
step a) to form a slurry
and c2), adding said slurry to the remaining film forming formulation.
Preferably, said slurry is
formed using high shear mixing such as mixing at a speed of at least 10000
rpm, such as e.g.
12000 rpm or more for at least 2 minutes.
Aspect 18. The method according to aspect 16 or 17, wherein said mixing in
step a) encompasses
high shear mixing, such as mixing at a speed of at least 15000 rpm, preferably
at least 20000 rpm
for at least 4 minutes.
Aspect 19. The method according to any one of aspect 16 to 18, wherein the
film-forming agent
comprises gelatin, pullulan, HPMCAS or HPMC.
Additionally, the film-forming solution further comprises one or more
additives such as: gelling
agents, gelling aids, viscosity modifiers, de-foaming aids, plasticizers,
lubricants, colorants,
solvents, solvent aids, surfactants, dispersants, solubilizers, stabilizers,
correctives, sweeteners,
adsorbents, adherent's, antioxidants, antiseptics, preservatives, desiccants,
flavors, perfumes, anti-
oxidants, pH adjusters, binders, disintegrating agents, release-controlling
agents.
Aspect 20. The method according to any one of aspects 16 to 19, wherein the
opacifier is present
in an amount of between 4 and 8 wt%, more preferably of between 5 and 7 wt%
based on final
dry weight of the film-forming composition.
Aspect 21. A method of making capsules comprising the steps of:
a) preparing a film forming composition according to the method of any one of
aspects 16 to 20
and
b) producing a capsule by means of dip molding. Typically, such a dip molding
method comprises
the steps of: dipping a mold pin in the film-forming composition at an
adequate temperature to
allow film-forming thereof on said dipping pin; (air-)drying said film on the
dipping pin; and
removing the film-formed capsule half from said dipping pin.
Aspect 22. The capsule according to aspect 13 or 14, or the capsule obtained
by the method of
aspect 21, wherein:
- when the capsule is an HPMC capsule having a calcium carbonate concentration
of about 5 or
10%, it typically will have an opacity coefficient of 20% or higher. An HPMC
capsule with 5%
CA 03100248 2020-11-13
WO 2019/219693 PCT/EP2019/062360
6
CaCO3 will typically have a light transmittance at 650 nm of 35% or lower,
while an HPMC capsule
having about 10% CaCO3 typically will have a light transmittance at 650 nm of
10% or lower.
- when the capsule is an HGC capsule having a calcium carbonate concentration
of about 5 or
10%, it typically will have an opacity coefficient of 17% or higher. An HGC
capsule with 10%
CaCO3 will typically have a light transmittance at 650 nm of 30% or lower,
while an HGC capsule
having about 5% CaCO3 typically will have a light transmittance at 650 nm of
55% or lower.
These values are determined on the average capsule wall thickness of standard
capsules, i.e. of
about 100 pm.
Aspect 23. The capsule according to aspect 22, filled with a filling
formulation comprising an active
ingredient such as a nutrient or a medicament.
Aspect 24. The capsule according to aspect 23, wherein the active ingredient
is present in an
amount ranging from about 0.05 wt% to about 100 wt% based on the total dry
weight of said
filling formulation. Typically, the active ingredient can present in an amount
ranging from about
0.5 wt% to about 90 wt% based on the total dry weight of said filling
formulation, preferably from
.. about 1 wt% to about 50 wt%, more preferably from about 5 wt% to about 30
wt% based on the
total weight of said filling formulation
Aspect 25. The capsule according to any of aspects 23 or 24, wherein the
active ingredient is an
active pharmaceutical ingredient, nutritional supplement, nutraceutical,
vitamin, mineral, cosmetic,
health food, preferably a light unstable active ingredient.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1: SEM images of different types of CaCO3 particles: A) precipitated
CaCO3 presenting
small uniform round/prismatic particles; B) encapsulated CaCO3 showing
agglomerated granules
forming large particles (up to 100 pm).
DETAILED DESCRIPTION OF THE INVENTION
Development of dosage forms such as capsules, with limited light
transmittance, e.g. to protect
light-unstable active ingredients is often a balancing act between opacity and
mechanical strength
and stability of the capsule shell.
The inventors have now identified the concentration range and type of calcium
carbonate that
provides a good balance to achieve both good opacifying effect and mechanical
strength
CA 03100248 2020-11-13
WO 2019/219693 PCT/EP2019/062360
7
It is to be understood that the terminology used herein is not intended to be
limiting, since the
scope of the present invention will be limited only by the appended claims.
As used herein, the singular forms "a", "an", and "the" include both singular
and plural referents
unless the context clearly dictates otherwise.
The terms "comprising", "comprises" and "comprised of" as used herein are
synonymous with
"including", "includes" or "containing", "contains", and are inclusive or open-
ended and do not
exclude additional, non-recited members, elements or method steps. The terms
also encompass
"consisting of" and "consisting essentially of".
The recitation of numerical ranges by endpoints includes all numbers and
fractions subsumed
within the respective ranges, as well as the recited endpoints.
The term "about" as used herein when referring to a measurable value such as a
parameter, an
amount, a temporal duration, and the like, is meant to encompass variations of
and from the
specified value, in particular variations of +/-10% or less, preferably +/-5%
or less, more
preferably +/-1% or less, and still more preferably +/-0.1% or less of and
from the specified
value, insofar such variations are appropriate to perform in the disclosed
invention. It is to be
understood that the value to which the modifier "about" refers is itself also
specifically, and
preferably, disclosed.
Whereas the term "one or more", such as one or more members of a group of
members, is clear
per se, by means of further exemplification, the term encompasses inter alia a
reference to any of
said members, or to any two or more of said members, such as, e.g., any 3, A,
5, or 7 etc.
of said members, and up to all said members.
The expression "low light transmittance" when used in combination with
capsules or capsule
formulations refers to capsules or capsule formulations that allow limited
light transmittance and
hence are to some extent capable of blocking light (e.g. natural or
artificial) from entering into the
cavity of the capsule body comprising the active ingredient. For a capsule
comprising 10wt.%
precipitated CaCO3 in its shell, typically an opacity coefficient of about 20%
or more is envisaged,
such as 25% or more, or 35% or more. Alternatively, the light transmittance
coefficient can be
indicated and implies the amount of light that is allowed to enter through the
capsule shell.
Typically a transmittance at 650 nm of below 35% is envisaged, preferably of
below 25%, such as
about 20% or less, or about 10% or less. For a capsule comprising 5wt.%
precipitated CaCO3 in
its shell, typically an opacity coefficient of about 15% or more is envisaged.
Alternatively, the light
transmittance coefficient can be indicated and implies the amount of light
that is allowed to enter
through the capsule shell. Typically a transmittance at 650 nm of below 55% is
envisaged.
CA 03100248 2020-11-13
WO 2019/219693 PCT/EP2019/062360
8
The opacity and transmittance of the capsules of the invention depend on the
type of film forming
polymer used and on the concentration of CaCO3 used. As an exemplary guidance:
when the capsule is an HPMC capsule having a calcium carbonate concentration
of about 5 or
10%, it typically will have an opacity coefficient of 20% or higher. An HPMC
capsule with 5%
CaCO3 will typically have a light transmittance at 650 nm of 35% or lower,
while an HPMC capsule
having about 10% CaCO3 typically will have a light transmittance at 650 nm of
10% or lower;
when the capsule is an HGC capsule having a calcium carbonate concentration of
about 5 or 10%,
it typically will have an opacity coefficient of 17% or higher. An HGC capsule
with 10% CaCO3 will
typically have a light transmittance at 650 nm of 30% or lower, while an HGC
capsule having about
5% CaCO3 typically will have a light transmittance at 650 nm of 55% or lower;
these values being determined on the average capsule wall thickness of
standard capsules, i.e. of
about 100 pm. There are several methods for measuring particle size and
particle size distribution.
Some of them are based on light, other on ultrasound, or electric field, or
gravity, or
centrifugation.
In all methods the size is an indirect measure, obtained by a model that
transforms, in abstract
way, the real particle shape into a simple and standardized shape, like a
sphere (the most usual)
or a cuboid (when minimum bounding box is used), where the size parameter (ex.
diameter of
sphere) makes sense. Exception is the mathematical morphology approach, where
no shape
hypothesis is necessary.
Definition of the particle size for an ensemble (collection) of particles
presents another problem.
Real systems are practically always polydisperse, which means that the
particles in an ensemble
have different sizes. The notion of particle size distribution reflects this
polydispersity. There is
often a need for a certain average particle size for the ensemble of
particles.
The term "D50 average particle size", or "Dv50", or volume basis median
particle size indicates
that in the particle mixture, the diameter of 50% (on the total mass) of the
particles is smaller
than, and the diameter of the other 50% (on the total mass) of the particles
is larger than the
indicated D50 average size. Typical measurement techniques are sieve analysis,
direct imaging and
laser diffraction known in the art.
The term "D4,3 average diameter size" or mean diameter over volume (also
called the DeBroukere
mean, following the conventions from ref. 2, ASTM E 799), is the mean particle
size based on the
volume distribution and implies that the volume mean is used to define the
central point of size
distribution, although the median is more frequently used than the mean when
using this
technique. The values for D[4,3] are strongly impacted by the presence of
aggregates which are
CA 03100248 2020-11-13
WO 2019/219693 PCT/EP2019/062360
9
not easily broken during measurement causing strong variation in measured
particles size in the
larger particles range. The equation is as follows:
ED4 1v#
1)1 -1,3] = 4
The term "particle size distribution", reflects the width or breadth of the
distribution or particle
sizes. Several calculations are used to describe the width of distribution but
the most common
calculations are standard deviation and variance.
The term "particle size span", indicates the broadness of particle size
distribution and follows the
equation: Span = (Dv0.9 - Dv0.1) / Dv0.5, wherein Dv0.9 (D90), Dv0.1 (D10) and
Dv0.5 (D50)
represent the size at which respectively 90%, 10% and 50% of the particles are
below said size, as
e.g. measured by laser diffraction.
The term "high shear mixing" encompasses any type of high shear mixing at a
speed of at least
15000 rpm, preferably at least 20000 rpm for at least 4 minutes. As a non-
limiting example one
can use the IKA Ultra Turraxx T25 mixer. The concentration of the dispersion
is preferably at least
wt%, preferably above 20 wt%.
15 All documents cited in the present specification are hereby incorporated
by reference in their
entirety.
Unless otherwise specified, all terms used in disclosing the invention,
including technical and
scientific terms, have the meaning as commonly understood by one of ordinary
skill in the art to
which this invention belongs. By means of further guidance, term definitions
may be included to
better appreciate the teaching of the present invention.
The film-forming agent referred to herein can by any type of film-forming
agent. Particularly
envisaged film-forming agents are gelatin, polysaccharides, modified starches,
or synthetic
polymers. Non-limiting examples thereof include generally known agents, for
example: cellulose
based polymers such as methyl cellulose, ethyl cellulose, methylhydroxyethyl
cellulose,
hydroxypropyl cellulose, hydroxypropyl methyl cellulose,
hydroxypropylmethylcellulose phthalate,
hydroxypropylmethylcellulose acetate succinate, carbownethylethylcellulose,
and the like,
polysaccharides such as pullulan, carrageenan, gellan, alginates, and the
like; or gelatin; synthetic
polymers such as polyvinyl alcohol, polyvinylacetal diethylamino acetate,
aminoalkylmethacrylate
copolymer E (Eudragit-E -Rohm Pharma Co. Ltd.), polyvinylpyrolidone, and the
like; (meth)acrylate
based polymers such as ethyl acrylate-methyl methacrylate copolymer
suspensions (Eudragit NE
(commercial name), Rohm Pharma Co. Ltd.), and the like; acrylate based
polymers such as
CA 03100248 2020-11-13
WO 2019/219693 PCT/EP2019/062360
methacrylate copolymer L (Eudragit L - Rohm Pharma Co. Ltd.), methacrylate
copolymer LD
(Eudragit L-30D55 - Rohm Pharma Co. Ltd.), and the like; as well as any
combination thereof.
Gelatin, pullulan and cellulose based polymers are preferred. Of said
cellulose based polymers,
methyl hyd roxyethylcel lu lose, hyd roxypropylcel lu lose,
hydroxpropylmethylcellulose, and
5 .. hydroxypropylmethylcellulose acetate succinate are more preferably used.
In addition to the film-forming agent(s), other additives can be added such as
plasticizers,
colorants, solvents, solvent aids, dispersants, solubilizers, stabilizers,
correctives, sweeteners,
adsorbents, absorbents, adherents, antioxidants, antiseptics, preservatives,
desiccants, flavors,
perfumes, pH adjusters, binders, lubricants, humectants, disintegrating
agents, and/or release-
10 controlling agents known in the art.
Adding additives such as dispersants (e.g. (iota-)carrageenan, sodium lauryl
sulfate, sorbitan, or
lecithin) can be beneficial.
When hard capsule shells are envisaged, said capsule shells may optionally
further include other
minor components conventionally used in capsules or that are used in the
aqueous composition for
.. dipping and that remain as part of the finished capsule. Examples of such
materials include
surfactants, de-foaming aids, anti-oxidants, viscosity modifiers, gelling
agents, gelling aids,
lubricants and plasticizers.
So called "setting systems" comprising gelling agents and/or gelling aids are
conventionally relied
upon in the manufacture of hard capsule shells by non-thermogelling dip-
molding processes to
.. confer an appropriate setting ability with cooling to film-forming polymers
(like pullulan, HPMC or
starch derivatives) that in these conditions have per se poor gelling
properties. The setting system
makes the aqueous composition to set on the dipped pins, thus enabling
capsules production and
assuring a uniform capsule shell thickness.
Such gelling agents and aids are well known in the art. Depending on the film-
forming polymers to
be used in the capsule shell manufacturing we refer to for example to U.S.
Pat. No. 5,264,223 and
EP714656 (discussing HPMC capsules), EP1117736 (discussing starch derivatives
capsules);
W02005105051 and EP1072633 (discussing pullulan capsules).
In one embodiment, the setting system of the invention comprises one or more
gelling agents. In
one embodiment, the setting system of the invention comprises one or more
gelling agents and
.. one or more gelling aids, also known as co-gelling agents.
In one embodiment, the one or more gelling agents are selected from the group
consisting of
alginates, agar gum, guar gum, locust bean gum (carob), carrageenan
(preferably kappa, lambda,
and/or iota), tara gum, arabic gum, ghatti gum, khaya grandifolia gum,
tragacanth gum, karaya
gum, pectin, arabian (araban), xanthan, low and high acyl gellan gum, starch,
konjac mannan,
CA 03100248 2020-11-13
WO 2019/219693 PCT/EP2019/062360
11
galactomannan, funoran, acetan, welan, rhamsan, furcelleran, succinoglycan,
scleroglycan,
schizophyllan, tamarind gum, curdlan, dextran and mixtures thereof.
Preferably, the one or more
gelling agents are selected from the group consisting of carrageenans
(preferably kappa and/or
iota, more preferably kappa-carrageenans), gellan gum and mixtures thereof. In
one embodiment,
the one or more gelling agents comprise, preferably consist of carrageenans
(preferably kappa
and/or iota, more preferably kappa-carrageenans). In one embodiment, the one
or more gelling
agents comprise, preferably consist of gellan gum.
In one embodiment, the one or more gelling agents comprise a combination of
two or more of the
agents listed above. In one embodiment, the one or more gelling agents
comprise, preferably
.. consist of a combination of xanthan and locust bean gum. In one embodiment,
the one or more
gelling agents comprise, preferably consist of a combination of xanthan with
konjac mannan.
In one embodiment, the one or more gelling aids (also known as co-gelling
agents) are cations. In
one embodiment, the one or more gelling aids are selected from the group
consisting of: K+, Li,
Na, NH4, Ca2+, Mg2+ and mixtures thereof. Preferably, the one or more gelling
aids are selected
from the group consisting of: K+, NH4, Ca2+ and mixtures thereof. The cations
can be added to
the setting system in the form of a pharmaceutically or food acceptable water
soluble salt (e.g.
chloride, acetate, citrate or phosphate).
In one embodiment, the setting system of the invention comprises one or more
gelling agents
selected from the group consisting of: carrageenans (preferably kappa and/or
iota, more
preferably at least kappa-carrageenans), gellan and mixtures thereof; and one
or more
pharmaceutically or food acceptable water soluble salts of K+, NH4, Ca2+ and
mixtures thereof.
In one embodiment, the aqueous composition of the invention contains one or
more gelling agents
as defined above in an amount suitable to obtain a hard capsule shell as
defined below containing
between about 0.01 and 3.0%, by weight, preferably between about 0.03 and
1.0%, by weight,
preferably between about 0.1% and 0.5% by weight of such gelling agent(s) over
the weight of
the shell. Exemplary suitable gelling agents' amounts are readily available to
a skilled person in the
field of hard capsules manufacturing. For example, it is commonly accepted
that hard capsule
shells containing a "target" amount of gelling agents falling within the
ranges identified above can
be obtained via a dip-molding process by using aqueous compositions containing
about 1/4 (i.e.
25%) of that target amount (expressed as % by weight over the weight of the
composition).
In one embodiment, the aqueous composition of the invention contains one or
more gelling aids as
defined above in an amount suitable to obtain a hard capsule shell as defined
below containing
about less than 3%, preferably about less than 2.0%, more preferably between
about 0.5% to
2.0%, even more preferably between about 1.0% and 2.0% by weight of such one
or more gelling
aids over the weight of the shell. In case the gelling aids are cations, the
above ranges are
CA 03100248 2020-11-13
WO 2019/219693 PCT/EP2019/062360
12
expressed as weight of the pharmaceutically or food acceptable water soluble
salts containing the
cation(s) over the weight of the shell. Exemplary suitable gelling aids
amounts are readily available
to a skilled person in the field of hard capsules manufacturing. For example,
it is commonly
accepted that when water is about 75% by weight over the weight of the aqueous
composition,
hard capsule shells containing a "target" amount of gelling aids can be
obtained via a dip-molding
process by using aqueous compositions containing about 1/4 (i.e. 25%) of that
target amount
(expressed as % by weight over the weight of the composition).
The hard capsule shells can also contain residual water. Typically such shells
comprise, for
example, less than 25 wt%, preferably less than 20 wt%, more preferably from 0
wt% to 14 wt%,
even more preferably from greater than 1wt% to less than 10 wt%, and more
preferably from 2
wt% to 7 wt% water by weight.
Although any active ingredient selected from active pharmaceutical
ingredients, nutritional
supplements, nutraceuticals, vitamins, minerals, cosmetics, health foods, or
the like can be
encapsulated in the capsule formulation of the present invention, light-
unstable or light-sensitive
ingredients are particularly suited. Non-limiting light-unstable medicaments
that can be filled in the
capsules to obtain effective light shielding are: dihydropyridine derivatives
(e.g., nifedipine),
antiviral HIV protease inhibitors (e.g., Ritonavir, Saquinavir), therapeutic
agents for hyperlipidemia
(e.g., clofibrate), iodine compounds (e.g., sodium iopodate, sodium iodide),
polyunsaturated fatty
acid derivatives (e.g., ethyl eicosapentaenoic acid (EPA), docosahexaenoic
acid (DHA)),
carotenoids (e.g., lycopene, bixin, [3-carotene, xanthophyll, lutein),
ubiquinones (coenzyme Q)(e.g.,
ubidecarenone used as a metabolizable cardiac stimulant), various vitamin
derivatives, as well as
indomethacin, colchicine, diazepam, syrosingopine, norethisterone, piretanide,
propericyazine,
perphenazine, mequitazine, medazepam, menatetrenone, indenolol hydrochloride,
reserpine,
sofalcone, bromocriptine mesilate, bufetolol hydrochloride and oxprenolol
hydrochloride when they
are filled into the capsule formulation of the present invention. Among
vitamin derivatives, fat-
soluble ones are preferred for use. Examples include vitamin A derivatives
(e.g., tretinoin, liver oil,
retinol palmitate), vitamin A analogs (e.g., etretinate), vitamin D
derivatives, vitamin E derivatives
(e.g., tocopherol nicotinate, tocopherol acetate, tocopherol calcium
succinate), and vitamin K
derivatives (e.g., phytonadione (vitamin K1), menaquinone (vitamin K2),
menadione (vitamin K3),
menatetrenone, phytonadione).
A medicament as an active ingredient can be filled into the capsules of the
present invention,
either alone or in combination with any base or carrier, additive, or
excipient. Any type of base or
carrier, either fat-soluble or water-soluble, can be used as long as it does
not impair the
medicament's activity and does not affect various physical properties of the
capsule shell, such as
strength, gas permeability, and disintegration or dissolution profiles.
Likewise, the base per se may
CA 03100248 2020-11-13
WO 2019/219693 PCT/EP2019/062360
13
be in a liquid or solid state at normal temperature as long as it can be
filled into capsules with the
help of heating or dilution with other solvents, etc. Examples of such a base
include vegetable oils
(e.g., soybean oil, sesame oil, cottonseed oil, olive oil), fatty acid
glycerides (e.g., medium chain
triglycerides), propylene glycol, propylene glycol fatty acid esters,
polyethylene glycol,
polyvinylpyrrolidone, triacetin, liquid paraffin, polyoxyethylene sorbitan
fatty acid esters, sucrose
fatty acid esters, ethanol and purified water, which may be used alone or in
combination. Bases
preferred for dissolving fat-soluble medicaments such as vitamins A, D, E and
K are vegetable oils
or fatty acid glycerides, with medium chain triglycerides being particularly
preferred. In the case of
using a water-soluble base, it is preferable to provide a protection layer
between the shell layer
and the medicament layer or a crystallization inhibitor in consideration of
influences on the capsule
shell.
A medicament to be filled into the capsule shell of the present invention is
preferably exemplified
by, but not limited to, those in a liquid form or those dissolved, suspended
or emulsified in such a
base as listed above. The medicament may also be in a solid form (e.g.,
powders, granules) or in a
semi-solid form (e.g., creams or gels).
The invention hence provides for a capsule formulation for forming capsules
with reduced light
transmittance (also called opaque capsules) comprising:
- a film forming agent as defined herein; and
- an opacifying agent in the form of calcium carbonate in an amount of between
3 and 10 wt%
based on dry weight of the capsule forming formulation. Preferably, said CaCO3
is present in an
amount of between 4 and 8% based on dry weight of the final capsule forming
formulation, more
preferably in an amount of between 4.5 and 6.5 wt% based on dry weight of the
final capsule
forming formulation.
As will become clear from the examples section, the amount and particle size
of the calcium
carbonate as well as the type of CaCO3 influences the balance between opacity
and mechanical
strength of the films and capsules envisaged herein.
The inventors have found that a median particle size (Dv50) of between 0.2 and
2.0 pm and/or a
D4,3 particle size of about 10 or less is particularly advantageous for
forming such films and
capsules.
The average particle size can be expressed as a "D50" (Dv50) median particle
size of between 0.2
to 2 pm, such as between 0.5 and 1.5 pm, more preferably of between 0.3 to 1.2
pm, more
preferably of between 0.4 to 1.1 pm, such as about 1 pm.
Alternatively, the particles can have a "D4,3" particle size of about 10 pm or
less, more preferably
of about 8 pm or less, such as about 6 pm or less, or about 4 pm or less, more
particularly of
CA 03100248 2020-11-13
WO 2019/219693 PCT/EP2019/062360
14
between 1 and 10 pm, or between 1 and 8 pm, preferably of between 2 and 6 pm,
more
preferably of about 4 pm, e.g. between 3.5 and 4.5 pm.
Preferably, said calcium carbonate has a substantially round/prismatic
particle shape. In a
particular embodiment, the calcium carbonate encompasses small uniform round
or prismatic
particles
Typically, the particle size span of the CaCO3 particles as defined above is
as low as possible.
Preferably, said span is below 10, preferably below 8, more preferably below
6.
In a preferred embodiment, the CaCO3 is precipitated, i.e. is prepared from
calcium oxide (CaO ¨
lime), whereto water is added to give calcium hydroxide. Subsequently carbon
dioxide is passed
through this solution to precipitate the desired calcium carbonate, in the
industry as precipitated
calcium carbonate (PCC). PCC is available in numerous crystal morphologies and
sizes, which can
be tailored to optimize performance in a specific application. The calcium
oxide used as starting
material for the precipitation process can be obtained through the milk of
lime process, which
encompasses crushing of high purity calcium carbonate rock into small
particles or powder suitable
for processing, heating the latter to about 1000 C, thereby taking the
calcium carbonate apart
into calcium oxide (CaO) and carbon dioxide (CO2) which can be captured and
reused in the
precipitation process above.
In a preferred embodiment, said PCC has a median particle size of between 0.2
and 2.0 pm or a.
D4,3 particle size of about 10 pm or less. Alternatively, the average particle
size of PCC can be
expressed as a "D50" (Dv50) median particle size of between 0.2 to 2 pm, such
as between 0.5
and 1.5 pm, more preferably of between 0.3 to 1.2 pm, more preferably of
between 0.4 to 1.1 pm,
such as about 1 pm.
The invention hence provides for a method of preparing a film-forming
composition with opacifying
capacities comprising the steps of:
a) preparing an aqueous dispersion of calcium carbonate opacifier through
mixing;
b) preparing a film-forming formulation comprising one or more film-forming
agent selected from
the group of: gelatin, polysaccharides, modified starches, (meth)acrylate
based polymers, or
synthetic polymers or a combination thereof;
c) adding the aqueous dispersion of step a) to the solution of step b); and
d) mixing the resulting dispersion of step c), thereby obtaining the film
forming composition,
comprising between 3 and 10 wt%, preferably of between 4 and 8 wt%, more
preferably of
between 5 and 7 wt%, such as from 4.5 to 6.5 wt% CaCO3 based on final dry
weight of the film-
forming composition. In one embodiment, said film-forming composition
comprises 15-25 wt%
CA 03100248 2020-11-13
WO 2019/219693 PCT/EP2019/062360
HPMC such as 20.5 wt% HPMC; or 25-35 wt%, such as about 31 wt% gelatin based
on total dry
weight of final capsule forming formulation.
In one embodiment, said film-forming composition comprises 15-25 wt% HPMC such
as 20.5 wt%
HPMC; or 25-35 wt%, such as about 31 wt% gelatin based on total dry weight of
final capsule
5 forming formulation.
In one embodiment, step c) is performed in two steps: c1) adding a part of the
film-forming
formulation of step b) to the dispersion of step a) to form a slurry and c2),
adding said slurry to
the remaining film forming formulation.
Preferably, said slurry is formed using high shear mixing such as mixing at a
speed of at least
10 10000 rpm, such as e.g. 12000 rpm or more for at least 2 minutes.
In one embodiment, said mixing in step a) encompasses high shear mixing, such
as mixing at a
speed of at least 15000 rpm, preferably at least 20000 rpm for at least 4
minutes.
Without wanting to be bound to any theory, the high shear mixing can result in
a better dispersion
of the CaCO3 in the film-forming composition, leading to increased mechanical
strength.
15 In one embodiment, the opacifier is present in an amount of between 3-10
wt%, such as between
4 and 8 wt%, more preferably of between 5 and 7 wt% based on final dry weight
of the film-
forming composition.
The invention also provides in a method of making capsules comprising the
steps of:
a) preparing a film forming composition as defined herein and
b) producing a capsule e.g. by the conventional processes like extrusion
moulding, injection
moulding, casting or dip moulding. Typically, such a dip molding method
comprises the steps of:
dipping a mold pin in the film-forming composition at an adequate temperature
to allow film-
forming thereof on said dipping pin; ((hot)-air-)drying of the said film on
the dipping pin; and
removing the film-formed capsule half from said dipping pin.
The capsules obtained through the methods as described herein typically will
have an opacity
coefficient of about 20% or higher and/or a light transmittance at 650 nm of
35% or lower when
e.g. a concentration of 10%w/w of precipitated calcium carbonate is used. When
using a lower
concentration of calcium carbonate such as about 5%, an opacity coefficient of
about 17% or
higher and/or a light transmittance at 650 nm of 55% or lower is reached. Said
ranges are based
on a capsule wall thickness of approximately 100 pm (e.g. from 90 pm to 110
pm) as is standardly
used for commercial capsules.
Such capsules can of course be used for delivery of any type of ingredient but
are particularly
suitable for active ingredients that have limited light-stability. Examples of
active ingredients can
CA 03100248 2020-11-13
WO 2019/219693 PCT/EP2019/062360
16
be active pharmaceutical ingredients, nutritional supplements, nutraceuticals,
vitamins, minerals,
cosmetics, health foods, or the like. Such an ingredient can be present in an
amount of between
0.05 wt% to up to 100wt /0. Typically, the active ingredient can present in an
amount ranging from
about 0.5 wt% to about 90 wt% based on the total dry weight of said filling
formulation,
preferably from about 1 wt% to about 50 wt%, more preferably from about 5 wt%
to about 30
wt% based on the total weight of said filling formulation.
In one embodiment, the capsules in which the opacifier is used are: HPMC-based
capsules such as
plant based capsules called VegiCaps, or Vcaps as described in US Patent
6,517,865; Vcaps Plus
as described in US Patent 9,655,860; Pullulan-based capsules such as those
described in US Patent
6,887,307; or enteric capsules such as Vcaps Enteric, described in
W02018/017799A1 and
W02013164121, the contents of which is hereby incorporated by reference. The
preferred
methods for producing such methods are also disclosed in said patents and
hereby incorporated by
reference.
The present invention is further illustrated in the following non-limiting
examples.
EXAMPLES
Materials and methods
Mechanical strength testing of films
Film mechanical properties were determined by tensile tests performed
according to ASTM D882 -
02 (using Instron 5965) on the samples that were stored at 22 C and 50%RH and
23%RH. Films
were stored at these conditions for 7 days. For most tensile testing of
materials, you will notice
that in the initial portion of the test, the relationship between the applied
force, or load, and the
elongation the specimen exhibits is linear. In this linear region, the line
obeys the relationship
defined as "Hooke's Law" where the ratio of stress (a) to strain (E) is a
constant, or according to
Hooke's law:
a
......... OW E
e.
"E" is the slope of the line in this region where stress (a) is proportional
to strain (E) and is called
the "Modulus of Elasticity" or "Young's Modulus".
Mechanical strength of Capsules
Test capsules are prepared as outlined below from the different film-forming
compositions using
conventional dip mold technology, wherein size 0 capsules are produced, having
a capsule side
wall thickness of about 100 pm. The mechanical strength of the manufactured
capsules was
CA 03100248 2020-11-13
WO 2019/219693 PCT/EP2019/062360
17
evaluated by the tube test method (internal impact method) In short, a weight
of 100 g is dropped
onto capsules (n=50) from a height of 8 cm and the number of broken capsules
are counted and
expressed as a percentage.
Capsules were stored at room temperature, at 2,5%, 10%, 23%, 33% and 45%
relative humidity
(RH) for 7 days. The measurements were done at room temperature.
Opacity testing
Opacity was measured by a spectrophotometer (Color Eye XTH Portable
Spectrophotometer) using
the phase-contrast imaging method. For the measurement of light transmittance,
the film samples
were placed in the light pathway in the UV-VIS spectrophotometer, and the
transmittance at 650
nm was recorded. Films were kept at room temperature.
For opacity testing, films of approximately about 100 pm thick were prepared
from the different
film-forming compositions as explained below. Such films correspond in terms
of thickness to the
side wall thickness of capsules ranging from 90-110 pm.
The term "opacity coefficient" as used herein corresponds to the Contrast
Ratio Opacity (OP), i.e.
the ratio between luminance or brightness measured against black and white
background. OP
measurements quantify how close to opaque a near-opaque material is.
The measurement is a two-part program metric where the Y (luminance or
brightness) value is
first measured on the sample backed by a black background, followed by a
second measurement
of the Y value of the sample backed by a white background. The resulting
fraction is expressed as
Y%, calculated as follows:
OP = Yblack backing/Ywhite backing X 100
Particles size measurement and imaging
Particles size was determined using laser diffraction method (Mastersizer
2000, Malvern). The
measurements were done on dry powder that was dispersed using the air pressure
of 2 bar.
Particles were imaged with a scanning electron microscope (SEM).
High shear mixing
High shear mixing of the opacifying solution or dispersion was done using an
Ultra Turrax T25
mixer (IKA) at a speed of 21000 rpm for at least 6 min. Concentration of the
dispersion is at least
15 wt%, preferably above 20 wt%.
Example 1: Film-forming formulation design
CA 03100248 2020-11-13
WO 2019/219693 PCT/EP2019/062360
18
CaCO3 was tested for its ability to induce opacity and for its effect on the
mechanical strength of
the polymeric films formed. This was tested on both cellulose-based (HPMC) and
gelatin-based
films.
A dispersion of non-encapsulated CaCO3 is first prepared and added to the film-
forming
formulation. The same general procedure is used for gelatin and HPMC
formulations.
In short, 60 g of water was added to 22.45 g of precipitated CaCO3 (PCC) and
the mixture was
homogenized with high shear mixing (e.g. high shear mixing at 21000 rpm (Ultra
Turax) for 3 x 2
minutes with 30 sec pause between each mixing).
Subsequently a part of (e.g. 20 g) of the liquid film-forming HPMC or gelatin
formulation,
comprising 20.5 wt% HPMC in water or 31 wt% gelatin in water is added and
mixed into the
dispersion under stirring at 12000 rpm (e.g. SiIverson apparatus), during e.g.
3 minutes, thereby
forming a slurry. Said slurry is then mixed with the remaining part of the
film-forming formulation,
thereby forming the film-forming composition resulting in a 10 wt% CaCO3
concentration based on
the final dry weight of said film-forming composition.
Encapsulated CaCO3 (10 wt% based on total dry weight of final capsule forming
formulation) was
dispersed in water by stirring with a helix mixer for about 45 minutes. The
required quantity of the
resulting dispersion was added to the liquid film-forming HPMC or gelatin
formulation, comprising
20.5 wt% HPMC in water or 31 wt% gelatin in water based on total dry weight of
final capsule
forming formulation, and mixed.
HPMC-based films were prepared as follows: glass plates were kept at 60 C, the
film-forming
composition comprising the different amounts of CaCO3 was kept at 28 C and
films were casted in
a warm reservoir (40-50 C) using e.g. a TLC plate coater, hand operated
(CAMAG, Muttenz, CH).
The films were then left to dry at 60 C for about 1 hour and kept overnight at
22 C, at a RH of
50%.
Gelatin films were formed as follows: glass plates were kept at 60 C, the film-
forming solution
comprising the different amounts of CaCO3 was kept at 55 C and films were
casted in a warm
reservoir (about 60 C) using e.g. a TLC plate coater (Camag CH). The films
were then left to dry
overnight at 22 C, at a RH of 50%.
The results of tests on HPMC and Gelatin (HGC) films are depicted in Table 1
below:
Polymer Opacifier wt%* Reported Opacity Transmittance --
Mechanical properties
particle (0/0) at 650 nm (%)
size (pm)
HPMC TiO2 2.0 0.1-1 61.4 0.7 5
CA 03100248 2020-11-13
WO 2019/219693 PCT/EP2019/062360
19
HPMC Precipitated CaCO3 10 0.7 32.8 7.9 -- 3
(PCC)
HPMC Encapsulated 10 3-5 37.05 9.3 1
agglomerated CaCO3
HGC TiO2 2.0 0.1-1 61.4 0.7 5
HGC Precipitated CaCO3 10 0.7 23.88 27.5 3
(PCC)
HGC Encapsulated 10 3 - 5 32.1 28.8 1
agglomerated CaCO3
HGC Ground CaCO3 10 3.8 21.7 19.8 1
* based on dry weight of total final capsule forming formulation
The score of 0 to 5 indicates the mechanical properties, 5 being the highest
score, 0 being the lowest score in terms of
mechanical properties.
HPMC stands for hydroxypropylmethylcellulose
HGC stands for hard gelatin capsule
The above results indicated that calcium carbonate shows potential as an
opacifier retaining
acceptable mechanical strength, although some differences were observed
between CaCO3 having
different particle size. Particularly interesting is that the encapsulated and
ground CaCO3 result in
less mechanical strength of the films.
In all further experiments, the term "precipitated CaCO3" refers to PCC as
indicated in Table 1.
Using scanning electron microscopy (SEM) imaging, the particle size and shape
of the different
CaCO3 compositions were analysed. To this end, the particles were coated with
metal and imaged
using a scanning electron microscope known in the art. The scale bar is given
in the images.
As follows from Figure 1, the particle size and shape of the CaCO3
compositions tested is quite
different: Figure 1 B shows agglomerated granules of the encapsulated CaCO3,
forming large
particles (up to 100 pm), while Figure 1 A shows much smaller particles of the
precipitated CaCO3
(PCC), having a small round/prismatic shape and being more uniform in particle
shape and size
distribution than the encapsulated CaCO3.
Next, the particle size of the different CaCO3 compositions was analyzed using
a laser diffraction
method as indicated above (cf. Table 2).
Table 2: Particle size and shape of precipitated and encapsulated CaCO3
CA 03100248 2020-11-13
WO 2019/219693 PCT/EP2019/062360
CaCO3 D50 (pm) D4,3 (pm) SEM remarks
precipitated CaCO3 0.91 6.19 Small,
(PCC) round/prismatic,
uniform particles
encapsulated CaCO3 9.9 33.9 ¨100 urn granules
made of 1 um
particles
Example 2: Tests on HPMC films and capsules:
5 Next, a study was done on the impact of different levels of calcium
carbonate on the films and
capsules properties.
For this, the same procedure as used for producing HPMC films according to
example 1 was used,
but with several calcium carbonate concentrations and types (PCC as in Table 1
or 2, or
encapsulated CaCO3). The following protocol was used to prepare the 10 wt%
CaCO3 in a 20.5
10 wt.% HPMC-based films:
HPMC solution
Step 1
HPMC 202.05g
Water 783.56 g
(cc of HPMC 20.5 wt%)
Step 2 Dispersion preparation
CaCO3 22.45 g
Water 60g
(cc of CaCO3 (PCC) 27.2 wt%)
Step 3 Slurry preparation
Dispersion from Step 2 82.45 g
HPMC solution from Step 1 20 g
Step 4 Final formulation
Polymer solution 965.61 g
CA 03100248 2020-11-13
WO 2019/219693 PCT/EP2019/062360
21
slurry 102.45 g
Result 10 wt% CaCO3 on 20.5 wt% HPMC capsule
In order to reach a film forming composition comprising 6.5 wt% of CaCO3 based
on the final dry
weight of said film-forming composition, step 4 of the above protocol is as
follows:
Step 1 HPMC solution
HPMC 322.93 g
Water 1252.36 g
(cc of HPMC 20.5 wt%)
Step 2 Dispersion preparation
CaCO3 22.45 g
Water 60 g
(cc of CaCO3 (PCC) 27.2 wt%)
Step 3 Slurry preparation
Dispersion from Step 2 82.45 g
HPMC solution from Step 1 20 g
Step 4 Final formulation
Polymer solution 1555.29 g
slurry 102.45 g
Result 6.5 wt% CaCO3 on 20.5 wt% HPMC capsule
In order to reach a film forming composition comprising 5 wt% or 7.5 wt% of
CaCO3 based on the
final dry weight of said film-forming composition, the above protocols can be
adjusted by changing
the relative amount of HPMC film-forming formulation vs. CaCO3 dispersion.
The opacity and light transmittance of the different HPMC-based films were
tested and the results
are presented in Table 3 below.
CA 03100248 2020-11-13
WO 2019/219693 PCT/EP2019/062360
22
Table 3: opacity and transmittance at 650 nm of HPMC films containing
different CaCO3 types at
two concentrations compared to transparent and films opacified with TiO2.
5% 10%
5% 10%
Transparent 2% TiO2 precip. precip. Encapsulated
Encapsulated
CaCO3 CaCO3
CaCO3 CaCO3
(PCC) (PCC) 3 5
Opacity (%)
15.09 63.09 23.3 32.8 25.07 37.05
Transmittance
90.1 0.7 26.6 7.9 27.3 9.3
at 650 nm (%)
Also the tensile properties of said films were tested using the Instron device
according to ASTM
D882-02. As shown in Table 4, the comparison between HPMC capsules comprising
5 or 10 wt%
precipitated or encapsulated CaCO3 does not show a marked difference in
tensile properties
because the HPMC films are by nature difficult to deform.
Table 4: Tensile properties of HPMC films with different CaCO3 concentrations
5% 10%
5% 10%
Transpar precip. precip.
2% TiO2 Encapsulated Encapsulated
ent CaCO3 CaCO3
CaCO3 CaCO3
(PCC) (PCC)
Young's
1800 1990 1862
modulus 1940 (98) (95) (70)
(80) 1803 (131.5) 1907 (158)
(MPa)(stdev)
%
50% 12.5 13.9 9.06 7.07 11 7.8
deformation
RH
(stdev) 3.3 2.9 1.16 1.1 2.9 1.5
Max %
18.8 20 11.73 9.8 14.7
11.12
deform.
Young
1852 2030 2081 2033 2056 2103
modulus
(175) (132) (89.9) (113) (85.9) (137)
(MPa)(stdev)
%
23% 13.25 12.93 9.6 7.8 10.8 7.2
deformation
RH
(stdev) 3 2.6 1.95 1.8 2.9 1.1
max %
19.8 17.4 12.8 11.2 16.9 9.93
deform.
Next, HPMC capsules were formed using a conventional mold-dipping technique
summarized in
here: The dip pins of size 0 are pre-heated at about 73 C, while the dipping
composition is
CA 03100248 2020-11-13
WO 2019/219693 PCT/EP2019/062360
23
maintained at 32 C. Capsules of size 0 are manufactured by the conventional
dipping process,
with pre-heated pins.
After the dipping, the capsules are dried with hot air at 60 C and 40% RH for
30 minutes and
then at about 22 C and 50% RH, for about 20 minutes.
The influence of precipitated CaCO3 and encapsulated CaCO3 on mechanical
strength when used at
wt% in HPMC capsules was compared and from the tube test evaluation it becomes
clear that
the precipitated CaCO3 is better for mechanical performance (less broken
capsules, cf. Table 5).
Table 5: comparison of effect of precipitated vs encapsulated CaCO3 on
mechanical strength of
HPMC-based capsules:
10 wt% CaCO3 % RH Total broken
capsules (%)
10 100
23 88.24
encapsulated CaCO3
33 47.06
45 0
10 96
precipitated CaCO3 23 46
(PCC) 33 10
45 0
The mechanical strength of HPMC-based capsules formed using a film-forming
composition
comprising 10 wt%, 7.5 wt% or 6.5 wt% precipitated CaCO3 (prepared according
to the protocols
of Examples 1 and 2) was subsequently tested using the tube test (internal
impact test) as
indicated above (Table 6).
Table 6: comparison of effect of different CaCO3 concentrations on mechanical
strength of HPMC-
based capsules:
wt% Precipitated
CaCO3 % RH Total broken
(PCC) capsules (%)
10 96
10% 23 46
33 10
45 0
2.5 94
10 82
7.5% 23 31
33 16
45 0
CA 03100248 2020-11-13
WO 2019/219693 PCT/EP2019/062360
24
2.5 90
68
6.5% 23 18
33 6
45 2
2.5 70
10 62
5.5% 23 8
33 4
45 2
Based on said results, we can summarize the conditions for calcium carbonate
to be effective in
HPMC capsules into a concentration range of between 3 and 10 wt% of
precipitated CaCO3, which
results in capsules with acceptable opacity and mechanical strength.
5
Example 3: Test on gelatin films: The film-forming composition and method from
Example 1
was used to produce gelatin films.
Step 1 gelatin solution (HGC melt preparation)
gelatin 322.94 g
Water 718.79g
(cc of gelatin 31 wt%)
Step 2 Dispersion preparation
CaCO3 22.45 g
Water 60 g
(cc of CaCO3 27.2 wt%)
Step 3 Slurry preparation
Dispersion from Step 2 82.45 g
gelatin solution from Step 1 20 g
Step 4 Coloring the formulation
Polymer solution 1021.71
slurry 102.45
Result 6.5 wt% CaCO3 on 30.1 wt% gelatin capsule
CA 03100248 2020-11-13
WO 2019/219693 PCT/EP2019/062360
Opacity and light transmittance at 650 nm were tested as explained above and
the results are
outlined in Table 7 below. Comparable results are obtained for precipitated
CaCO3 (PCC as in Table
1 or 2) and encapsulated CaCO3.
Table 7: opacity and transmittance at 650 nm of gelatin-based films
5% 10% 5% 10%
Transparent 2% TiO2 precip. precip. Encapsulated
Encapsulated
CaCO3 CaCO3 CaCO3 CaCO3
Opacity (%) 15.83 62.4 18.96 23.88 24.15 32.1
Transmittance at
82.2 1.7 49.2 27.5 48.5 28.8
5
Tensile tests on films were done as explained above for the HPMC films and
show that films with
precipitated CaCO3 can be deformed more than films containing encapsulated
CaCO3 (cf. Table 8).
Table 8: Tensile properties of gelatin-based films with different CaCO3
concentrations
2% 5% 10% 5% 10%
Transparent TiO2 precip. precip. Encapsulated
Encapsulated
CaCO3 CaCO3 CaCO3 CaCO3
Young's
3032 2483 2507
modulus 2359 (123)
2510.7 (91.2) 2600 (125)
(127) (145.5) (145.3)
(MPa)(stdey)
%
50% RH deformation 24.5 12.44 15.9 13.3 11.8
11.5
(stdey) 10.9 5 6,7 4.5 5 2.1
Max % def 47.3 27.28 30.4 21.4 24.6
15.1
Young
3112 2784
modulus 2398 (141) 2861 (126) 2521 (112.7)
2601 (151)
(MPa)(stdey)
(122) (127)
%
23% RH deformation 41.8 23 14.8 12.9 12.8
14.86
(stdey) 11.2 9.4 5.9 6.3 5.8 6.1
max % def 58.6 44.44 27.4 28.8 28.6
27.4
This film-forming composition can also be used to produce gelatin-based
capsules through
conventional mold dipping. In short, by dipping stainless steel mold pins at
room temperature (at
about 22 C) into a hot liquid gelatin solution (e.g. about 45 C), a film of
controlled dimensions is
CA 03100248 2020-11-13
WO 2019/219693 PCT/EP2019/062360
26
formed on the mold. After drying, this results in capsule halves with shell
wall thickness of about
100 pm.
Example 4: Industrial scale test
Using the same film-forming composition as in Example 2, 550,000 HPMC capsules
size 0 and
625,000 HPMC capsules size 1, were manufactured with a good quality and
acceptable opacity.
Overall trial outcomes are hence very positive.
